v3.25.2
Discontinued Operations - Sale of Infusionz to Bloomios (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2022
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Jun. 30, 2024
Jun. 30, 2023
Jul. 01, 2023
Oct. 28, 2022
Acounts receivable balance $ 760,729 $ 180,897   $ 180,897   $ 606,885 $ 1,125,394 $ 2,046,700  
Income from discontinued operations   0 $ 268,155 0 $ 917,966 1,164,184 (1,370,124)    
Interest rate 8.50%                
Common stock   $ 1,430   $ 1,430   $ 1,045 1,011    
Discontinued Operations [Member]                  
Maturity date           October 26, 2024      
Acounts receivable balance           $ 845,443      
Income from discontinued operations           $ 71,976 $ (338,418)    
Original principal amount                 $ 5,000,000
Series D Convertible Preferred Stock                 8,500,000
Series D Convertible Preferred Stocks           85,000      
Senior secured convertible debenture           $ 4,500,000     4,500,000
Convertible secured subordinate promissory note percentage           8.50%      
Convertible secured subordinate promissory note conversion price per share           $ 5.00      
Convertible secured subordinate promissory note annual percentage           40.00%      
Interest rate           10.00%      
Reserve           $ 1,179,498      
Original principal amount, after OID                 779,117
Common stock purchase warrant                 2,853,910
Common stock                 8,500,000
Convertible preferred stock description           stated value per share of $100 and we are to receive dividends equal to 8.5% per year on a monthly basis, 30 days in arrears      
Valuation allowance                 8,500,000
Unpaid interest                 35,385
Accrued interest                 $ 449,484